Cardioprotective effect of crude polysaccharide fermented by Trametes Sanguinea Lyoyd on doxorubicin-induced myocardial injury mice

Figures

• 

  Fig. 1. The content of TSLFACP. A Standard curve of glucose concentration. B Determination data of TSLFACP content (n = 3)

• 

  Fig. 2. TSLFACP alleviates myocardial injury induced by DOX in vitro. A The effects of TSLFACP in different concentrations on the proliferation of H9C2 cells. B The effect of TSLFACP on the DOX-induced injury in the cardiomyocytes H9C2 cells. C The effect of TSLFACP on the DOX-induced injury in embryonic myocardial cell line CCC-HEH-2. D The morphology of H9C2 cells treated by DOX and TSLFACP (100 ×). The data is expressed as the x ± s (n = 4). *P < 0.05, ***P < 0.001 vs control; ##P < 0.01, ###P < 0.001 vs DOX

• 

  Fig. 3. TSLFACP alleviates myocardial injury induced by DOX in vivo. A Changes in body weight of mice in the three groups. B Image of H&E staining on the heart tissue section of mice in these three groups (100 ×). C The level of cTnI in the serum of mice in each group. The data is expressed as the x ± s (n = 6). *P < 0.05, vs control, #P < 0.05 vs DOX

• 

  Fig. 4. TSLFACP alleviates DOX-induced myocardial injury by reducing autophagy. A Intensity of LC3A spots expression in heart tissue samples (100 ×) and the number of LC3A spots was assessed. B Western blot analysis of autophagy-related proteins, the samples derive from the same experiment and that blots were processed in parallel, and blots shown were cut. *P < 0.05, **P < 0.01, ***P < 0.001 vs control, #P < 0.05, ###P < 0.001 vs DOX

• 

  Fig. 5. TSLFACP alleviates DOX-induced myocardial injury by reducing apoptosis. A Tunel staining in heart tissue samples (200 ×). B Western blot analysis of apoptosis-related proteins, the samples derive from the same experiment and that blots were processed in parallel, and blots shown were cut. ***P < 0.001 vs control, ##P < 0.01, ###P < 0.001 vs DOX